More details on GSK-3 - Revision history

59.93.79.177: /* Overview */

2006-07-14T14:05:18Z

‎Overview

Vinod.singh@dolcera.com: /* Role of beta catenin */

2006-07-14T11:45:34Z

‎Role of beta catenin

Vinod.singh@dolcera.com: /* Role of beta catenin */

2006-07-14T11:43:56Z

‎Role of beta catenin

Vinod.singh@dolcera.com: /* Ways to inhibit GSK3 */

2006-07-14T11:26:31Z

‎Ways to inhibit GSK3

Vinod.singh@dolcera.com: /* Structure */

2006-07-14T11:26:15Z

‎Structure

Vinod.singh@dolcera.com: /* Structure */

2006-07-14T11:25:28Z

‎Structure

Vinod.singh@dolcera.com: /* Structure */

2006-07-14T11:25:00Z

‎Structure

Vinod.singh@dolcera.com: /* Beta-catenin */

2006-07-14T11:24:30Z

‎Beta-catenin

Vinod.singh@dolcera.com: /* Beta-catenin */

2006-07-14T11:22:46Z

‎Beta-catenin

Vinod.singh@dolcera.com at 11:18, 14 July 2006

2006-07-14T11:18:11Z

← Older revision		Revision as of 14:05, 14 July 2006
Line 1:		Line 1:
	=Overview=		=Overview=
−	Glycogen synthase kinase-3 (GSK-3) has recently emerged, in the field of medicinal chemistry, as one of the most attractive therapeutic targets for the development of selective inhibitors as promising new drugs for numerous serious pathologies, including Alzheimer's disease, stroke, bipolar disorders, chronic inflammatory processes, cancer, alopecia and Type II diabetes. The full potential of GSK-3 inhibitors is yet to be realised and the number of drug candidates being developed by both academic centres and pharmaceutical companies has increased exponentially in the last three years. This review discloses recent discoveries on peptides and small molecules targeting GSK-3. Antisense therapy for the modulation of GSK-3 expression is also discussed. Focusing attention on this exciting target could thus reap considerable clinical and economic rewards.	+	Glycogen synthase kinase-3 (GSK-3) has recently emerged, in the field of medicinal chemistry, as one of the most attractive therapeutic targets for the development of selective inhibitors as promising new drugs for numerous serious pathologies, including Alzheimer's disease, stroke, bipolar disorders, chronic inflammatory processes, cancer, alopecia and Type II diabetes. The full potential of GSK-3 inhibitors is yet to be realised and the number of drug candidates being developed by both academic centres and pharmaceutical companies has increased exponentially in the last three years. This review discloses recent discoveries on peptides and small molecules targeting GSK-3. Antisense therapy for the modulation of GSK-3 expression is also discussed. Focusing attention on this exciting target could thus reap considerable clinical and economic rewards. [http://www.expertopin.com/doi/abs/10.1517/13543776.16.6.773 source]

@@ Line 87: / Line 87: @@
 * In the absence of β-catenin, stem cells can differentiate into the epidermal lineage but not into the hair follicular lineage. [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=154144 source]
 * In a research, expression of stabilized β-catenin in the epidermis of transgenic mice resulted in hair follicle morphogenesis. [http://www.biomedcentral.com/1471-2121/7/4#B8 source]
 [[image:in action.jpg|center|400 px]]

← Older revision		Revision as of 11:43, 14 July 2006
Line 87:		Line 87:
	* In the absence of β-catenin, stem cells can differentiate into the epidermal lineage but not into the hair follicular lineage. [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=154144 source]		* In the absence of β-catenin, stem cells can differentiate into the epidermal lineage but not into the hair follicular lineage. [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=154144 source]
	* In a research, expression of stabilized β-catenin in the epidermis of transgenic mice resulted in hair follicle morphogenesis. [http://www.biomedcentral.com/1471-2121/7/4#B8 source]		* In a research, expression of stabilized β-catenin in the epidermis of transgenic mice resulted in hair follicle morphogenesis. [http://www.biomedcentral.com/1471-2121/7/4#B8 source]
		+
		+	[[image:in action.jpg\|center\|400 px]]

@@ Line 55: / Line 55: @@
 Possible ways in the art to inihibit GSK3 is illustrated in following figure:
-[[image:ways to inhibit gsk3.jpg|center|300 px]]
+[[image:ways to inhibit gsk3.jpg|center|500 px]]
 =Beta-catenin=

← Older revision		Revision as of 11:26, 14 July 2006
Line 59:		Line 59:

	==Structure==		==Structure==
		+	Beta-catenin consists of 781 amino acid residue.

	[[image:catenin.jpg\|500 px\|center]]		[[image:catenin.jpg\|500 px\|center]]

@@ Line 60: / Line 60: @@
 ==Structure==
-[[image:catenin.jpg|300 px|center]]
+[[image:catenin.jpg|500 px|center]]
 '''Amino Acid Sequence'''

← Older revision		Revision as of 11:22, 14 July 2006
Line 74:		Line 74:
	721 SGGYGQDALG MDPMMEHEMG GHHPGADYPV DGLPDLGHAQ DLMDGLPPGD SNQLAWFDTD<br>		721 SGGYGQDALG MDPMMEHEMG GHHPGADYPV DGLPDLGHAQ DLMDGLPPGD SNQLAWFDTD<br>
	781 l		781 l
		+
		+	==Role of beta catenin==
		+
		+	* Stabilized β-catenin can induce new hair follicles and trichofolliculoma-like tumors in skin. [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=154144#B33 source]
		+	* Follicular (hair) and epidermal stem cells are located in the bulge region.
		+	* In the absence of β-catenin, stem cells can differentiate into the epidermal lineage but not into the hair follicular lineage. [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=154144 source]
		+	* In a research, expression of stabilized β-catenin in the epidermis of transgenic mice resulted in hair follicle morphogenesis. [http://www.biomedcentral.com/1471-2121/7/4#B8 source]

← Older revision		Revision as of 11:18, 14 July 2006
Line 52:		Line 52:
	[[image:gsk-3 sequence.jpg\|center\|800 px]]		[[image:gsk-3 sequence.jpg\|center\|800 px]]

		+	== Ways to inhibit GSK3==
		+	Possible ways in the art to inihibit GSK3 is illustrated in following figure:
		+
		+	[[image:ways to inhibit gsk3.jpg\|center\|300 px]]
	=Beta-catenin=		=Beta-catenin=